Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSCW) Cash & Current Investments (2020 - 2025)

Historic Cash & Current Investments for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to $1.7 million.

  • Ensysce Biosciences' Cash & Current Investments fell 5971.64% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 5971.64%. This contributed to the annual value of $3.5 million for FY2024, which is 21168.25% up from last year.
  • Latest data reveals that Ensysce Biosciences reported Cash & Current Investments of $1.7 million as of Q3 2025, which was down 5971.64% from $2.2 million recorded in Q2 2025.
  • Ensysce Biosciences' Cash & Current Investments' 5-year high stood at $12.3 million during Q4 2021, with a 5-year trough of $1.0 million in Q2 2024.
  • Moreover, its 5-year median value for Cash & Current Investments was $3.3 million (2022), whereas its average is $4.7 million.
  • As far as peak fluctuations go, Ensysce Biosciences' Cash & Current Investments skyrocketed by 1269756.23% in 2021, and later crashed by 8322.74% in 2023.
  • Quarter analysis of 5 years shows Ensysce Biosciences' Cash & Current Investments stood at $12.3 million in 2021, then plummeted by 74.34% to $3.1 million in 2022, then plummeted by 64.3% to $1.1 million in 2023, then soared by 211.68% to $3.5 million in 2024, then plummeted by 52.22% to $1.7 million in 2025.
  • Its Cash & Current Investments was $1.7 million in Q3 2025, compared to $2.2 million in Q2 2025 and $3.1 million in Q1 2025.